Formulations:

• Ceftazidime Vials:
  • Strengths: 250mg, 500mg, and 1000mg
  • Product Form: Lyophilized powder for reconstitution for intravenous administration
  • Packing Specs: Available in vial packs of 1’s

Indications:

Ceftazidime is indicated for the treatment of various bacterial infections caused by susceptible organisms, including:

• Respiratory tract infections, such as pneumonia and bronchitis
• Urinary tract infections, including cystitis and pyelonephritis
• Skin and soft tissue infections, including cellulitis and wound infections
• Intra-abdominal infections, such as peritonitis
• Septicemia and meningitis
• Bone and joint infections
• Endocarditis (in combination with other antibiotics)

Pharmacokinetics:

• Absorption: Ceftazidime is not absorbed orally and must be administered via intravenous or intramuscular routes.
• Distribution: The drug distributes widely into various body tissues and fluids, achieving therapeutic concentrations in the lungs, kidneys, and cerebrospinal fluid.
• Metabolism: Ceftazidime undergoes minimal metabolism in the body, with the majority of the drug excreted unchanged in the urine.
• Elimination: The elimination half-life of ceftazidime is approximately 1-2 hours in adults with normal renal function.

Pharmacodynamics:

• Ceftazidime exerts its bactericidal effect by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell death.

Usage:

• Ceftazidime vials are intended for intravenous administration after reconstitution with a suitable diluent.
• Healthcare professionals should follow the recommended dilution and infusion rates provided in the prescribing information.

Dosage:

• The dosage of Ceftazidime varies depending on the type and severity of the infection, as well as the patient’s age, weight, and renal function.
• Dosage adjustments may be necessary in patients with impaired renal function to prevent drug accumulation and toxicity.

Side Effects:

• Common side effects of Ceftazidime may include:
  • Gastrointestinal disturbances, such as nausea, vomiting, and diarrhea
  • Skin rash and allergic reactions
  • Superinfections, including fungal infections
• Serious side effects such as anaphylaxis and pseudomembranous colitis may occur, although they are rare.

Experience the effectiveness and reliability of AIT Pharmaceuticals Division’s Ceftazidime Range in the management of bacterial infections. For more information, please contact us.